Purdue jumps ahead in pain drug race

With three significant development programs at work on a tamper-free alternative to the blockbuster OxyContin franchise, Purdue Pharma is bracing for an upcoming FDA panel review of its new pain therapy formulation. Pain Therapeutics, Alpharma and Elite Pharmaceuticals all hope to gain approvals for their own therapies, notes Pharmalot. But Purdue plans to beat them to it.

No one knows exactly what makes the new Purdue therapy tamper-proof, but there have been hints about a certain "rubbery" quality to the new drug. Just a year ago executives with Purdue pleaded guilty to charges that they had misled regulators on the addictive risks presented by OxyContin, which brought in a billion dollars in sales last year.

- check out the report in Pharmalot

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.